Catalent, Inc. (NYSE: CTLT), a provider of delivery technologies and development solutions to the pharmaceutical industry, has reported earnings for the third quarter of 2023.
- The company reported a net loss of $227 million for the third quarter, compared to a profit of $141 million a year earlier
- On a per-share basis, it was a loss of $1.26 for the March quarter vs. earnings of $0.78 in the year-ago quarter
- The adjusted net loss was $0.09 per share, compared to net income of $1.04 per share in Q3 2022
- Third-quarter net revenue decreased 19% year-over-year to $1.04 billion
- Q3 adjusted EBITDA came in at $105 million, which is down 69% from the corresponding period of 2022
- For fiscal 2023, the management expects net revenue to be in the range of $4.225 billion to $4.325 billion
- The forecast for full-year adjusted net income is $169-210 million
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
What to expect when J.M. Smucker (SJM) reports Q2 2025 earnings results
Shares of The J.M. Smucker Co. (NYSE: SJM) stayed red on Friday. The stock has dropped 6% over the past three months. The branded foods company is slated to report
Earnings Summary: Highlights of BJ’s Wholesale Club’s Q3 2024 results
Department store chain BJ’s Wholesale Club Holdings, Inc. (NYSE: BJ) has reported financial results for the third quarter of 2024, reporting a 3% increase in net sales. Adjusted earnings, on a
